9th September 2024 BNCM announces today the expansion of DELEX PHARMAs medical device business through its strategic partnerships with leading international medical device companies in the US and Germany. These collaborations are expected to contribute around 30% of the companys total revenue, reinforcing DELEXs rapid growth in the healthcare sector.
The Philippine medical device market is experiencing substantial growth, driven by increasing demand for advanced imaging technologies. The market is projected to grow at a Compound Annual Growth Rate (CAGR) of 9.14% from 2024 to 2029, reaching a market volume of USD 1.036 billion by 2029, according to Statista.
The fluid management market in the Philippines is growing due to increasing healthcare needs, rising prevalence of chronic diseases, and advancements in medical technology. The market size and growth in the Philippines is projected to reach approximately USD100 million by 2025, growing at a CAGR of around 8% from 2023 to 2025, according to MarketsandMarkets.
Hence, DELEX has also partnered with Amsino, a California-based global leader in fluid management, medication delivery, and patient care solutions. Amsinos FDA-qualified facilities and 25 years of expertise bring a range of innovative products to the Philippine market through DELEX PHARMA.
Amsino Products includes the Suction and Fluid Management (Receptal Trolleys & Liners, Receptal Canisters, iReceptal): Suction and fluid management play a critical role in healthcare, particularly in settings such as hospitals and clinics where effective management of bodily fluids is essential for patient care.
The medical device market in the Philippines for 2024 is valued at approximately USD670 million and is expected to grow at a CAGR of around 8.4% from 2024 to 2029, according to Statista. To propel market development, DELEX PHARMA has further strengthened its portfolio by partnering with SternMed GmbH, a German company specializing in high-quality medical devices and turnkey healthcare solutions. This partnership includes:
Since establishing its medical device division in 2015, the company has introduced various advanced technologies, starting with the CADD-Solis infusion systems from Smiths Medical. Over the years, DELEX PHARMA has diversified its offerings by adding Philips Ultrasound for Cardiology and Neutraclear needleless connectors from CAIR LGL. These expansions highlight DELEX PHARMA’s dedication to delivering a wide range of innovative and cutting-edge medical technologies to the market.
These strategic partnerships underscores DELEX PHARMA’s commitment to providing innovative and reliable medical solutions, reinforcing its leadership and influence in the Philippine pharmaceutical and medical device industries.
BNCM is an Asset Management Company that secures its assets by investing in companies with strong growth potentials, robust revenues, significant profits, proven track records, and promising business models with highly experienced management teams that will exceptionally qualify for quotation and listing on the OTC or NASDAQ markets within the next 2 to 3 years. The growth of these companies will directly provide more employment opportunities to the communities, improve the country’s economy, and bring greater social change.
For more information, visit: https://www.bncm.net/
DELEX is a Delaware-registered company, and the holding company of DLX Holdings, Inc. (DLX). DLX is a Philippine-based parent company that holds a 60% controlling interest in Delex Pharma International, Inc. an ISO 9001-2015 Certified company, which also holds a controlling interest in JMN Brother’s Pharma Limited, Inc. DLX and its subsidiaries are involved in the development and distribution of pharmaceutical and healthcare products in the Philippines.
For more information, visit: https://delexhealth.com
